home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Fighting Fibrosis

  August, 27 2009 19:33
your information resource in human molecular genetics

A potential new target for drugs aiming to treat lung fibrosis is reported in Nature Medicine.

NADPH oxidases (NOX) are enzymes that catalyze the production of free radicals. The free radicals may have beneficial effects, such as fighting pathogens, or deleterious consequences, such as triggering cell death.

Victor Thannickal and his colleagues report a role for one type of NOX -- called NOX-4 -- in lung fibrosis. They found that NOX-4 is necessary for the generation of hydrogen peroxide, which triggers myofibroblast differentiation and extracellular matrix production, both hallmarks of fibrosis. NOX-4 is up-regulated in the lungs of patients with lung fibrosis. Moreover, genetic and pharmacologic targeting of NOX-4 prevented fibrosis in two mouse models of this disease.

These findings support a role for NOX-4 in tissue fibrosis and provide a starting point for therapeutic targeting of NOX-4 in lung fibrosis, a disease for which there is no available treatment.

Author Contact:

Victor Thannickal (University of Alabama at Birmingham, AL, USA)
E-mail: vjthan@uab.edu

Abstract available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.